TL;DR: The biochemistry, epidemiology, and genetic and extrinsic influences on plasma fibrinogen levels, as well as the close association between plasma fibinogen and various vascular disorders are reviewed.
Abstract: Plasma fibrinogen is an important component of the coagulation cascade, as well as a major determinant of blood viscosity and blood flow. Increasing evidence from epidemiological studies suggests that elevated plasma fibrinogen levels are associated with an increased risk of cardiovascular disorders, including ischaemic heart disease (IHD), stroke and other thromboembolism.1,,2 This increase in plasma fibrinogen levels may promote a prothrombotic or hypercoagulable state, and may in part explain the risk of stroke and thromboembolism in conditions such as atrial fibrillation (AF).
Nevertheless, the relationship between hyperfibrinogenemia, atherosclerosis and thrombosis is complicated. As the process of thrombogenesis is very closely related to atheroma formation (atherogenesis), it follows that specific thrombogenic factors such as fibrinogen (with important effects on blood rheology) may play key roles in the process of atherosclerotic lesion formation, with subsequent effects on cardiovascular diseases (Figure 1). However, knowledge about the precise determinants of plasma fibrinogen levels in health and disease is as yet incomplete, and many paradoxes are still present. For example, it is known that plasma fibrinogen is higher in Black than in White patients,3 but (in the UK at least) coronary artery disease is less common in Blacks than in White patients, while hypertension and stroke are conversely more common.4,,5 Plasma fibrinogen is also influenced by many factors: it increases with age, body mass index, smoking, diabetes and post menopause and is related to fasting serum insulin, low-density-lipoprotein (LDL) cholesterol lipoprotein(a) and leukocyte count. Conversely, it decreases with moderate alcohol intake, physical activity, increased high-density-lipoprotein (HDL) cholesterol, and with hormone replacement therapy (HRT).6–,8 Figure 1.
Plasma fibrinogen, thrombogenesis and atherogenesis.
We review the biochemistry, epidemiology, and genetic and extrinsic influences on plasma fibrinogen levels, as well as the close association between plasma fibrinogen and various vascular disorders. …
Address correspondence to Professor G.Y.H. Lip, Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH. e-mail: g.y.h.lip{at}bham.ac.uk
TL;DR: Plasma fibrinogen levels are raised via intravenous infusion and induced thrombosis by ferric chloride application to the carotid artery or saphenous vein to suggest a causative role for hyperfibrinogens in acute thromBosis and have significant implications for thrombolytic therapy.
TL;DR: Combined hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess may contribute to the high incidence of vascular disease sequelae experienced by dialysis patients, which is inadequately explained by traditional CVD risk factors.
TL;DR: Findings provide direct experimental evidence that hyperfibrinogenemia is more than a by-product of cardiovascular disease and may function independently or interactively to modulate the severity and/or progression of vascular disease.
TL;DR: The results might support the idea that hyperfibrinogenemia can augment lymphatic and hematogeneous metastasis of advanced gastric cancer, which is major determinant of the prognosis in T2 Gastric cancer.
Abstract: Abnormal hemostasis in cancer patients has previously been described, however the correlation between the plasma fibrinogen level and cancer metastasis and prognosis has not been reported in a large-scale clinical study. Preoperative plasma fibrinogen levels were retrospectively examined in 405 patients who underwent surgery for advanced gastric cancer. The association of fibrinogen levels with clinical/pathological findings and clinical outcome was evaluated. There was a positive correlation between plasma fibrinogen levels and the depth of invasion (p 310 mg/dl) was independently associated with lymph node (Odds Ratio; 2.342, P = 0.0032) and liver (Odds Ratio; 2.933, P = 0.0147) metastasis, not with peritoneal metastasis in this series. Patients with hyperfibrinogenemia showed worse clinical outcome in T2 gastric cancer, however, there was no correlation of plasma fibrinogen level with prognosis in T3/T4 gastric cancer. Our results might support the idea that hyperfibrinogenemia can augment lymphatic and hematogeneous metastasis of advanced gastric cancer, which is major determinant of the prognosis in T2 gastric cancer. Therefore, in the situation without peritoneal involvement, hyperfibrinogenemia is a useful biomarker to predict the possible metastasis and worse clinical outcome in T2 gastric cancer.